Tandem Diabetes Care, Inc. (TNDM) Operating Margin
- Operating margin · 12 months: Value -4.40%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4.40% | Operating income / revenue. Period ending 2026-06-30. $-45.80M ÷ $1.04B × 100 ≈ -4.40% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -45.80M USD | Operating Income (Loss) |
| Revenue | 1.04B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 458.10M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 441.37M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-45.80M | $1.04B | $458.10M | (m) | $441.37M | -4.40% |
| 2026-03-31 | $-83.81M | $1.03B | $463.14M | (m) | $439.32M | -8.16% |
| 2025-12-31 | $-187.26M | $1.01B | $468.72M | (m) | $444.99M | -18.45% |
| 2025-09-30 | $-196.13M | $1.01B | $470.99M | (m) | $437.73M | -19.48% |
| 2025-06-30 | $-199.36M | $1.00B | $475.35M | (m) | $428.93M | -19.90% |
| 2025-03-31 | $-178.33M | $982.95M | $469.64M | (m) | $413.57M | -18.14% |
| 2024-12-31 | $-99.13M | $940.20M | $450.63M | (m) | $389.82M | -10.54% |
| 2024-09-30 | $-133.60M | $854.35M | $428.94M | (m) | $369.74M | -15.64% |
| 2024-06-30 | $-139.06M | $796.00M | $405.49M | (m) | $349.43M | -17.47% |
| 2024-03-31 | $-147.09M | $770.01M | $390.55M | (m) | $352.80M | -19.10% |
| 2023-12-31 | $-233.23M | $747.72M | $380.03M | (m) | $352.50M | -31.19% |
| 2023-09-30 | $-215.95M | $771.42M | $381.51M | (m) | $364.44M | -27.99% |
| 2023-06-30 | $-231.90M | $790.35M | $385.76M | (m) | $369.22M | -29.34% |
| 2023-03-31 | $-205.33M | $794.69M | $389.89M | (m) | $352.22M | -25.84% |
| 2022-12-31 | $-92.85M | $801.22M | $388.23M | (m) | $335.68M | -11.59% |
| 2022-09-30 | $-62.33M | $790.71M | $379.52M | (m) | $309.49M | -7.88% |
| 2022-06-30 | $-7.12M | $765.79M | $362.28M | $120.33M | $290.31M | -0.93% |
| 2022-03-31 | $10.55M | $737.67M | $343.65M | $107.25M | $276.22M | 1.43% |
| 2021-12-31 | $22.65M | $702.80M | $326.58M | $92.05M | $261.51M | 3.22% |
| 2021-09-30 | $28.58M | $660.87M | $307.83M | $79.94M | $244.53M | 4.32% |
| 2021-06-30 | $19.85M | $604.84M | $283.23M | $71.93M | $229.83M | 3.28% |
| 2021-03-31 | $2.38M | $541.94M | $258.39M | $67.42M | $213.75M | 0.44% |
| 2020-12-31 | $-7.96M | $498.83M | $238.31M | $63.57M | $204.90M | -1.60% |
| 2020-09-30 | $-24.48M | $439.16M | $208.93M | $58.77M | $195.95M | -5.57% |
| 2020-06-30 | $-29.47M | $410.22M | $194.61M | $54.71M | $190.37M | -7.18% |
| 2020-03-31 | $-19.30M | $394.24M | $183.12M | $49.93M | $180.49M | -4.90% |
| 2019-12-31 | $-16.72M | $362.31M | $168.09M | $45.20M | $165.74M | -4.62% |
| 2019-09-30 | $-18.30M | $330.11M | $154.63M | $41.43M | $152.35M | -5.54% |
| 2019-06-30 | $-28.01M | $281.71M | $135.13M | $37.39M | $137.21M | -9.94% |
| 2019-03-31 | $-40.14M | $222.58M | $110.81M | $32.64M | $119.27M | -18.03% |
| 2018-12-31 | $-44.63M | $183.87M | $94.04M | $29.23M | $105.23M | -24.27% |
| 2018-09-30 | $-54.77M | $147.96M | $82.21M | $26.18M | $94.35M | -37.02% |
| 2018-06-30 | $-52.23M | $128.70M | $72.87M | $23.10M | $84.97M | -40.58% |
| 2018-03-31 | $-57.20M | $115.90M | $67.16M | $21.51M | $84.44M | -49.36% |
| 2017-12-31 | $-62.94M | $107.60M | $63.51M | $20.66M | $86.38M | -58.50% |
| 2017-09-30 | $-66.71M | $96.22M | $59.53M | $19.25M | $84.14M | -69.33% |
| 2017-06-30 | $-81.95M | $81.51M | $58.27M | $20.50M | $84.70M | -100.55% |
| 2017-03-31 | $-80.04M | $83.17M | $59.75M | $19.77M | $83.69M | -96.24% |
| 2016-12-31 | $-78.05M | $84.25M | $60.66M | $18.81M | $82.83M | -92.64% |
| 2016-09-30 | $-75.92M | $84.46M | $57.47M | $18.60M | $84.31M | -89.90% |
| 2016-06-30 | $-66.21M | $87.88M | $53.80M | $17.54M | $82.75M | -75.35% |
| 2016-03-31 | $-67.83M | $80.60M | $49.90M | $17.27M | $81.26M | -84.16% |
| 2015-12-31 | $-69.00M | $72.85M | $46.27M | $16.96M | $78.62M | -94.72% |
| 2015-09-30 | $-75.29M | $61.62M | $41.96M | $16.75M | $78.19M | -122.18% |
| 2015-06-30 | $-75.59M | $59.42M | $40.88M | $16.16M | $77.97M | -127.22% |
| 2015-03-31 | $-75.24M | $53.97M | $36.77M | $15.99M | $76.44M | -139.42% |
| 2014-12-31 | $-75.66M | $49.72M | $34.47M | $15.79M | $75.12M | -152.17% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-49.43M | $29.01M | $22.84M | $11.08M | $44.52M | -170.42% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-33.05M | $2.48M | $3.82M | $9.01M | $22.69M | -1335.27% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |